financetom
Business
financetom
/
Business
/
Brazilian lender Bradesco's net income rises 4.4% in Q2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brazilian lender Bradesco's net income rises 4.4% in Q2
Aug 5, 2024 5:34 AM

SAO PAULO, Aug 5 (Reuters) - Brazilian lender Bradesco

reported higher than expected second-quarter net

profit on Monday, driven by lower loan-loss provisions and

stronger margins.

Bradesco's recurring net profit - which excludes one-off

impacts in income - in the April-June period rose 4.4% on a

yearly basis to 4.7 billion reais ($820.55 million), it said in

a securities filing, slightly ahead of the 4.4 billion reais

forecast by analysts polled by LSEG.

During the quarter, the Osasco-based lender had to set aside

7.3 billion reais for loans that are likely to default, 29.3%

less than the figure reported a year ago and 6.7% below the

previous quarter.

Bradesco's consolidated loan book grew 5.0% year-on-year to

912.1 billion reais, boosted by loans to individuals and

medium-sized enterprises.

But net interest income, earnings on loans minus deposit

costs, was down 5.9% to 15.6 billion reais.

After a series of weak earnings pressured by rising

delinquency and higher costs, Bradesco installed a new chief

executive at the end of last year and began implementing a plan

to gradually recover its profitability.

"We continued to execute our strategic plan, the benefits of

which will partially appear in our operational results in 2024

and on a larger scale from 2025," Bradesco said in a statement.

Bradesco said it has kept its full-year outlook unchanged,

including expectations that its consolidated loan book will grow

by between 7% and 11% this year.

($1 = 5.7279 reais)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Meta Platforms Threads Reportedly Major Beneficiary of Recent Exodus by Former X Users
Meta Platforms Threads Reportedly Major Beneficiary of Recent Exodus by Former X Users
Nov 26, 2024
04:01 PM EST, 11/26/2024 (MT Newswires) -- Meta Platforms' ( META ) Threads has been adding millions of new users in recent weeks as many internet denizens look for alternatives to X/Twitter since the US elections, multiple media outlets reported Tuesday. Threads has added around 35 million new users during November, including about 20 million people starting accounts on the...
Graphic Packaging Holding Insider Sold Shares Worth $355,800, According to a Recent SEC Filing
Graphic Packaging Holding Insider Sold Shares Worth $355,800, According to a Recent SEC Filing
Nov 26, 2024
04:04 PM EST, 11/26/2024 (MT Newswires) -- Charles D Lischer, Senior Vice President and Chief Accounting Officer, on November 25, 2024, sold 12,000 shares in Graphic Packaging Holding ( GPK ) for $355,800. Following the Form 4 filing with the SEC, Lischer has control over a total of 49,849 shares of the company, with 49,849 shares held directly. SEC Filing:...
Netflix defeats shareholder lawsuit over growth forecasts
Netflix defeats shareholder lawsuit over growth forecasts
Nov 26, 2024
(Reuters) - Netflix ( NFLX ) won the dismissal on Tuesday of a shareholder lawsuit accusing the streaming company of downplaying the impact on subscriber growth of account sharing, where paying members share user names and passwords with nonpaying members in other households. The proposed class action led by a Texas-based trustee began after Netflix ( NFLX ) revealed in...
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
Nov 26, 2024
04:00 PM EST, 11/26/2024 (MT Newswires) -- Shares of Amgen ( AMGN ) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said. Amgen ( AMGN ) announced that its investigational drug, MariTide, demonstrated up to 20% average weight loss over a 52-week...
Copyright 2023-2026 - www.financetom.com All Rights Reserved